111 results
8-K
EX-99.1
IRWD
Ironwood Pharmaceuticals Inc - Ordinary Shares
15 Feb 24
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
7:04am
below and at the end of this press release.
Net profit for the LINZESS U.S. brand collaboration, net of commercial and research and development (“R&D”) expenses … . brand collaboration, net of commercial and R&D expenses, was $749.9 million for the full year 2023, compared to $695.7 million for the full year 2022
8-K
EX-99.1
IRWD
Ironwood Pharmaceuticals Inc - Ordinary Shares
8 Jan 24
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
6:05am
patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.
Founded
8-K
EX-99.2
IRWD
Ironwood Pharmaceuticals Inc - Ordinary Shares
8 Jan 24
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
6:05am
2022 2023 LINZESS brand profitability (incl. R&D) LINZESS U.S. net sales LINZESS continues to generate strong brand profits LINZESS demand is increasing … & Ironwood commercial costs, expenses and other discounts 2 77,736 223,142 AbbVie & Ironwood R&D expenses 3 9,264 28,270 Total net profit on sales of LINZESS
CORRESP
IRWD
Ironwood Pharmaceuticals Inc - Ordinary Shares
30 Nov 23
Correspondence with SEC
12:00am
and development (“R&D”) expenses related to LINZESS in the United States that are shared equally between the Company and AbbVie. Also as set forth … the sales of LINZESS in the United States, including the commercial costs and expenses and the R&D expenses related to LINZESS in the United States
8-K
EX-99.1
ppvgh9z4y06p
9 Nov 23
Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
7:07am
8-K/A
EX-99.1
vmj2c1g
11 Sep 23
Index to Financial Statements
4:30pm
8-K
EX-99.1
w8yvk9 hz4
8 Aug 23
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
7:08am
8-K
EX-99.1
bzs5ok
30 Jun 23
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
4:05pm
SC TO-T/A
EX-99
qyafq3ek1 z85s6slkx
29 Jun 23
Third party tender offer statement (amended)
8:32am
SC TO-T/A
EX-99
1x91h2bdkbwlmr0fwj5
16 Jun 23
Third party tender offer statement (amended)
7:09am
SC TO-C
EX-99.4
t7oxhn
22 May 23
Information about tender offer
5:00pm
SC TO-C
EX-99.1
5isfsoir3 b6aj
22 May 23
Information about tender offer
5:00pm
SC TO-C
EX-99.5
ivfin65f euvs1z3
22 May 23
Information about tender offer
5:00pm
SC TO-C
EX-99.2
vuanv9j5qligt8ent
22 May 23
Information about tender offer
4:26pm
8-K
EX-99.2
ii2 c2wwo
22 May 23
Entry into a Material Definitive Agreement
4:25pm
8-K
EX-99.1
3dclwz4sscilk 4isx7n
4 May 23
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
7:12am
8-K
EX-99.1
ow0d1wom3m3
3 Nov 22
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
7:00am
8-K
EX-99.1
bxvgyi hw
4 Aug 22
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
7:06am